INTRODUCTION
Invasive fungal infections (IFIs) continue to represent a significant problem in immunosuppressed individuals. It has been estimated that more than 90 % of all IFIs are caused by Aspergillus and Candida species (Beck-Sagué & Jarvis, 1993; Goodrich et al., 1991; Singh, 2001; Vincent et al., 1998) . Early detection of the fungal pathogen is crucial for appropriate antifungal therapy and thus the clinical outcome of patients with IFI (Morace et al., 1997) . Conventional diagnostic tests, including blood cultures (Duthie & Denning, 1995; Vincent et al., 1998) and serological detection of circulating fungal antigens (e.g. D- glucan or galactomannan) (Pfeiffer et al., 2006) , have shown variable sensitivity and specificity. Histological analyses of computed tomography-guided biopsies are highly sensitive and specific, but are frequently associated with bleeding complications in patients with severe thrombocytopenia (Denning, 1998) . Therefore, efforts are ongoing to develop less invasive, yet reliable, sensitive and specific diagnostic tests for IFIs to overcome the limitations of the traditional fungus detection methods. Recently, a variety of PCR-based methods have been developed for rapid and sensitive detection of fungal pathogens (Chryssanthou et al., 1994; Einsele et al., 1997; Jordan, 1994; Sandhu et al., 1995) . Since non-albicans Candida spp. and non-fumigatus Aspergillus spp. are increasing in importance (Bille et al., 2005; Coleman et al., 1998; Torres et al., 2003) , diagnostic approaches covering a large number of fungal species are required. Broad-spectrum PCR methods mostly exploit the highly conserved regions of the ribosomal multi-copy rDNA gene cluster to amplify numerous fungal strains by a universal primer set (Medlin et al., 1988) . approaches; however, a lot of published assays only permit detection of single fungal species (Costa et al., 2001; Loeffler et al., 2000; Spiess et al., 2003) . To date, some TaqMan RQ-PCR methods covering either multiple Candida (Maaroufi et al., 2004; White et al., 2003) or Aspergillus species (Costa et al., 2002; Kami et al., 2001) are available. Earlier studies relying on LightCycler technology have demonstrated the principle feasibility of detecting moulds and yeasts in a single reaction (Jordanides et al., 2005; Klingspor & Jalal, 2006) . Our assay, however, is based on TaqMan technology employing a short universal hydrolysis probe localized within a highly conserved fungal region, which minimizes the effect of point mutations on the detectability of the fungal species. Based on comprehensive sequence analysis of the fungal 28S rDNA genes, we have been able to establish an assay permitting the detection and monitoring of at least nine clinically relevant Candida species and six Aspergillus species. Our panAspergillus and pan-Candida assay (Pan-AC assay; patent pending) permits economic fungus screening and accurate quantification of a broad range of pathogenic Aspergillus and Candida species in the clinical setting.
METHODS
Fungal strains, bacteria and virus isolates. Fungal strains for PCR testing were obtained from the American Type Culture Collection (ATCC) and from the German Collection of Micro-organisms (DSM, Germany): A. fumigatus (ATCC 36607), Aspergillus niger (ATCC 10535), C. albicans (ATCC 14053), Candida dubliniensis (ATCC MYA-646), Candida glabrata (ATCC 2001), Candida krusei (ATCC 6258), Candida parapsilosis (ATCC 22019) and Candida tropicalis (ATCC 750), and Aspergillus flavus (DSM 818), Aspergillus nidulans (DSM 820), Aspergillus terreus (DSM 826), Aspergillus versicolor (DSM 1943), Candida guilliermondii (DSM 70051), Candida kefyr (DSM 70073) and Candida lusitaniae (DSM 70102). Prior to DNA extraction, the fungal isolates were cultured on Sabouraud dextrose agar at 30 uC; Candida isolates were cultured for 48 h and Aspergillus isolates for 72 h. Suspensions of all fungi (Candida species, cell suspension; Aspergillus species, conidia suspension) were prepared using an aliquot of cultured fungus resuspended in sterile 0.9 % NaCl solution.
In addition, a panel of bacterial and viral micro-organisms were selected for testing of cross-reactivity. The panel included Enterobacter aerogenes, Eschericha coli, Haemophillus influenzae, Listeria monocytogenes, Pseudomonas aeruginosa, Salmonella enteritidis, Staphylococcus aureus, Streptococcus pneumoniae, Proteus vulgaris, human adenoviruses, Epstein-Barr virus, cytomegalovirus, varicella-zoster virus, herpes simplex virus types 1 and 2, and parvovirus B19 (PVB19).
Clinical materials. The clinical specimens from patients with documented fungus infections were obtained upon informed consent. The specimens included biopsies of pulmonary infiltrations (n52) and peripheral blood (n53) from haemato-oncological patients, bronchotracheal secretions (n511) from intensive care patients, and a cornea control specimen with a culture-documented infection by Fusarium solanii, which is outside the detection spectrum of the Pan-AC assay (kindly provided by St Anna Children's Hospital, Vienna, Austria and the Institute of Hygiene and Medical Microbiology, Medical University of Vienna, Austria). Peripheral blood specimens from healthy volunteer donors were used to test for cross-reactivity with human DNA.
DNA extraction. All steps were performed in a laminar flow hood. Reagents used for extraction were filtered through 0.2 mm sterile filters.
(i) Fungal strains. A colony of each fungus culture was homogenized in 500 ml lyticase lysis buffer (LLB) [50 mM Tris (pH 7.6), 1 mM EDTA (pH 8.0), 0.2 % 2-mercaptoethanol, 10 U ml 21 recombinant lyticase (Sigma)] and incubated at 37 uC for 1 h. After incubation, acid-washed glass beads 710-1180 mm in diameter (Sigma) were added and vortexed thoroughly for 2 min. A total of 400 ml supernatant were used for DNA extraction on a MagNA Pure compact instrument using the MagNA Pure compact nucleic acid isolation kit I (Roche Diagnostics) as described by the manufacturer. The DNA was eluted in a total volume of 100 ml elution buffer (Roche Diagnostics). DNA concentrations were determined by a PicoGreen dsDNA quantification kit (Molecular Probes) and fluorescence spectrophotometer F-2500 (Hitachi).
(ii) Blood specimens. After hypotonic lysis of the erythrocytes from 3 ml blood using red cells lysis buffer [10 mM Tris (pH 7.6), 5 mM MgCl 2 , 10 mM NaCl], as described by Loffler et al. (1997) , the leukocytes were pelleted and resuspended in 470 ml LLB. The subsequent procedure followed the extraction protocol described above.
(iii) Respiratory secretions. Samples were centrifuged at 5000 g for 10 min. The supernatant was removed and 430 ml LLB was added. The extraction was performed as described above.
(iv) Lung biopsies and cornea. Solid material was mechanically disrupted and homogenized in 16 PBS. The samples were centrifuged at 5000 g for 10 min, the supernatant was removed and 430 ml LLB was added. The subsequent steps were as described above.
(v) Bacteria and viruses. For the isolation of DNA from cultured bacteria and virus stocks, a commercially available kit (QIAamp DNA mini kit; Qiagen) was used as recommended by the manufacturer.
Target sequence analysis and primer/probe design. Conserved nucleotide sequences of the fungal ribosomal multi-copy genes (18S, 5.8S and 28S) of clinically relevant Aspergillus and Candida species were selected and aligned using the BLAST search software, freely accessible at http://www.ncbi.nlm.nih.gov/BLAST/. Within the 28S large ribosomal subunit [between nucleotides 146 and 311 based on the sequence of the 28S rDNA gene of C. albicans (NCBI accession no. Z48339)], a highly conserved region was identified that spans less than 150 bp in length, thereby optimally fitting the requirements of RQ-PCR analysis using a hydrolysis TaqMan probe. Sequences for the forward primer, the reverse primer, and the universal probe were selected using Primer Express software (version 2.0; Applied Biosystems) following the manufacturer's guidelines ( Table 2 ). The probe was labelled with FAM (6-carboxyfluorescein) as a reporter molecule at the 59-end and TAMRA (6-carboxytetramethylrhodamine) as a quencher molecule at the 39-end (Applied Biosystems). The optimal concentrations for the primers and the probe were assessed by serial analyses both from the functional and economic perspective, and were specified at 400 and 200 nM, respectively.
RQ-PCR. PCR reactions were set up in a total volume of 25 ml containing 12.5 ml universal master mix [26 concentration, including ROX-reference dye and uracil N9-glycosylase (UNG)] (Applied Biosystems), 1 % formamide, a mixture of the forward and the reverse primer (400 nM each), 200 nM Pan-AC hydrolysis probe, and 5 ml genomic DNA (gDNA).
The mixture was transferred to 96-well optical microtitre plates (Applied Biosystems). Amplification was performed on the ABI 7700 sequence detection system (Applied Biosystems) using the following cycling parameters: 2 min at 50 uC (degradation of potentially present contaminating dUTP-containing amplicons by UNG), 10 min at 95 uC (inactivation of UNG and activation of AmpliTaq Gold DNA polymerase), followed by 50 cycles of 15 s at 95 uC and 60 s at 60 uC for target amplification. For absolute quantification of the fungal DNA, standard curves were prepared using serial logarithmic dilutions covering a range of five logs (10 fg-100 pg) gDNA derived from C. albicans and A. fumigatus as positive control samples.
Assessment of the detection limit. To determine the detection limit of fungal pathogens in peripheral blood, 1 ml EDTA-anticoagulated whole blood from healthy volunteer donors was spiked with tenfold serial dilutions of A. fumigatus conidia and C. albicans cells (10 5 to 1 cell). The number of fungal particles was determined microscopically using a counting chamber. DNA extraction was performed according to the protocol outlined above.
Controls. A number of precautions were undertaken to control the occurrence of false-positive results. Multiple no-template and non-homologous template controls were processed together with the specimens tested, as described previously (Watzinger et al., 2004) . To document the efficiency of DNA extraction and amplification, various positive controls were included, as already published (Lion, 2001) . In clinical samples containing human cells, a single-copy housekeeping gene (b2-microglobulin) was co-amplified in parallel with the fungal targets (Lion, 2001 ). For largely cell-free human specimens, defined concentrations of a seal herpes virus were spiked into the sample prior to DNA extraction and analysed by RQ-PCR to control for the potential occurrence of inhibitory effects (Watzinger et al., 2004) .
RESULTS AND DISCUSSION
In the present report, a RQ-PCR assay is described permitting the detection and quantification of a broad range of clinically relevant Aspergillus and Candida species (Table 1) in a single Fig. 1 . Alignment of a highly conserved region within the 28S rDNA gene of six Aspergillus species, ten Candida species and the corresponding region from the human genome. The primer pair and the probe (grey boxes) for the Pan-AC RQ-PCR assay were placed within this region. The indicated nucleotide positions refer to the sequence of C. albicans (NCBI accession no. Z48339). The asterisks indicate species that are listed under another name in the NCBI database: A. nidulans5NCBI Emericella nidulans; C. guilliermondii5NCBI Pichia guilliermondii; C. kefyr5NCBI Kluyveromyces marxianus; C. krusei5NCBI Issatschenkia orientalis; C. lipolytica5NCBI Yarrowia lipolytica; C. lusitaniae5NCBI Clavispora lusitaniae. 
reaction. A single primer pair and a universal probe were designed within a highly conserved region of the 28S large ribosomal subunit (Fig. 1) . The selected primer and probe sequences display a degenerated code (Table 2) , which was a prerequisite for sensitive detection of fungal species differing from others at single nucleotide positions.
Specificity of the Pan-AC assay
The ability of the Pan-AC system to detect all fungus species of interest was determined by testing DNA derived from cultures of reference strains, including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, C. guilliermondii, C. kefyr, Candida lipolytica, C. lusitaniae, C. dubliniensis, A. fumigatus, A. flavus, A. niger, A. terreus, A. versicolor and A. nidulans. Target sequences of all species were amplified successfully and showed nearly identical amplification efficiencies (data not shown). Based on the sequence alignment of additional, less common Aspergillus and Candida species, the Pan-AC RQ-PCR assay can be expected to cover several other members of these two genera with similar sensitivity.
The Pan-AC primers and probe were evaluated for possible cross-reactivity with bacterial or viral pathogens, both by sequence alignment using the BLAST software, and experimentally by testing the Pan-AC assay against bacterial and viral DNA from different organisms (see Methods). No crossreactivity between the Pan-AC primer/probe detection system and non-fungal pathogens was observed (data not shown). As indicated in Fig. 1 , DNA sequences from different human genes show significant homology with the fungal DNA sequence targeted by the Pan-AC assay. Analysing human DNA extracted from peripheral blood of healthy volunteer donors initially revealed some degree of crossreactivity. Different chemicals, including DMSO, glycerol and formamide, were tested in different concentrations (1-5 %) to increase the stringency of the PCR reaction without simultaneously compromising the overall amplification efficiency. DMSO and glycerol completely inhibited the PCR reaction even at low concentrations (data not shown). By contrast, formamide concentrations of 1 % abrogated the cross-reactivity with human DNA, while maintaining the high amplification efficiency of the PCR assay (Table 3 ). This concentration of formamide was, therefore, included both in the assessment of the detection limit and the testing of clinical specimens by the Pan-AC assay.
Detection limit of the assay
The detection limit of the Pan-AC assay was determined by testing serial dilutions of fungal gDNA derived from organisms representing yeasts (C. albicans) and moulds (A. fumigatus). The DNA concentration of the two fungal species was determined by fluorometric measurements, and serial logarithmic dilutions across a range of five logs (10 fg 2100 pg) were prepared. After PCR amplification, the cycle threshold (C T ) values of individual dilutions steps were plotted against the template amount, leading to typical standard curves (Fig. 2) . The y intercept, which corresponds to the theoretical limit of detection, was determined at C T 38.9 for A. fumigatus and C T 37.9 for C. albicans. In view of the inter-assay variability of the technique in the range of ±1 C T , this difference can be regarded as minor. The amplification efficiencies of the Candida and Aspergillus species listed in Table 1 revealed only marginal differences (data not shown). The standard curves presented are, therefore, applicable in quantitative analysis of all fungal species covered by the Pan-AC assay. The lowest template amount permitting accurate and reproducible quantification of fungal DNA was in the order of 10 fg.
In order to investigate the applicability of the Pan-AC assay to the analysis of clinical specimens, peripheral blood from Table 3 . Influence of formamide concentration on the C T and the fluorescence intensity of the reporter (DRn)
The effect of formamide was tested for different fungal DNA template concentrations of both Candida and Aspergillus representatives ranging from 1 pg to 10 fg. The RQ-PCR results shown represent the effect of formamide observed at the lowest fungal template concentration tested (10 fg C. albicans DNA). Although the overall fluorescence intensity decreased with rising concentrations of formamide, the concentration at which any cross-reactivity with human DNA was abrogated (1 %) generally revealed only slightly increased C T values. healthy volunteer donors was spiked with tenfold serial dilutions of A. fumigatus conidia and C. albicans cells, covering a range between 10 5 to 1 organism ml
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. The DNA was extracted and amplified as described in Methods. In patients with IFI, the fungal load in peripheral blood samples is generally low, often below 10 c.f.u. ml 21 (Loeffler et al., 2000) . Based on these observations, the sensitivity of the PCR assay is crucial for the detection and quantification of fungal pathogens. The detection limit of the Pan-AC assay in spiking experiments was less than 10 organisms per PCR reaction; however, for reproducible detection and quantitative analysis a higher volume of peripheral blood providing larger overall number of fungal organisms was beneficial (data not shown).
Analysis of clinical specimens
The Pan-AC assay was employed to investigate specimens from 17 haemato-oncological or intensive care patients with fungal infections diagnosed by other methodological approaches, including primarily culture techniques and DNA sequencing. According to the EORTC criteria, 4 patients were classified as having a possible IFI and 12 patients a probable IFI infection (Table 4 , samples 1-16). Only for the patient from whom the cornea specimen was derived, was no EORTC classification available (Table 4 , sample 17).
The Pan-AC assay revealed positive results in the clinical specimens studied, including lung biopsies of patients with pulmonary aspergillosis or candidiasis, peripheral blood specimens from patients with different types of candidaemia, and respiratory secretions positive for different Aspergillus species (Table 4 ). In one of the latter specimens, co-infection with C. lusitaniae was detected (Table 4 , sample 13). The only clinical sample that tested negative by the Pan-AC assay was a cornea specimen, in which culture analysis revealed the presence of F. solanii. This specimen only served as a control because this fungus is not within the detection spectrum of the PCR assay presented (Table 4 ). Quantitative analysis of the fungal load in specimens positive by RQ-PCR was performed by using the appropriate standard curves, and the amount of fungal DNA determined was translated to the number of organisms on the basis of the estimated mean genome masses of Aspergillus and Candida species of 32 and 37 fg, respectively.
Prevention and control of contamination
A major problem of fungal PCR assays is the high risk of contamination (Loeffler et al., 1999) , which is attributable to the ubiquitous presence of airborne fungal spores, and traces of fungal DNA in a variety of reagents and other consumables. To avoid false-positive results, it is imper- ative therefore to control all materials used, both self-made and commercially available, for fungal contaminants, and to include multiple negative controls in each assay. The fungus detection assays must be performed under adequate experimental conditions, which include the preparation of reagents and processing of clinical samples under a laminar flow biohazard hood. With appropriate precautions and controls, the RQ-PCR assay presented can serve as a reliable diagnostic tool for the detection and quantitative monitoring of pathogenic fungi in clinical specimens.
In view of its broad specificity, the Pan-AC assay could serve as a screening technique for the presence of IFI. In patients testing positive, antifungal agents, such as voriconazole or caspofungins, could be used as first-line treatment, because these substances can be expected to cover the entire range of fungi detected by this assay. The use of agents with a narrower spectrum of antifungal activity, such as fluconazole or amphotericin B, would require the identification of the fungal species present, which can be performed by a number of molecular techniques, including, for example, the analysis of the variable ITS2 region or species-specific hybridization (Chen et al., 2000; Elie et al., 1998; Sandhu et al., 1995; Turenne et al., 1999) .
In comparison to most earlier RQ-PCR approaches to the detection of invasive aspergillosis or candidiasis (Bu et al., 2005; Buchheidt et al., 2004; Kami et al., 2001; Kasai et al., 2006; Klingspor & Jalal, 2006; Spiess et al., 2003) , the Pan-AC assay covers a considerably larger spectrum of pathogenic Aspergillus and Candida species in a single reaction, using a universal detection probe and a single primer pair. Our data indicate that the Pan-AC assay can be readily implemented in routine clinical diagnosis and monitoring of the majority of IFIs.
NOTE ADDED IN PROOF
While this paper was in press, a paper by SchabereiterGurtner et al. (2007) was published, in which a similar technique is described. 
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DThe numbers indicate the determined amount of fungal DNA at the beginning of the PCR-reactions. To calculate the fungal load in the clinical specimen investigated, the quantity of fungal DNA in fg assessed by RQ-PCR analysis can be translated to the number of fungal organisms on the basis of the estimated genome mass and the appropriate dilution factor of the sample analysed.
